Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …

Cytokines have long been used for therapeutic applications in cancer patients. Substantial
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …

Recombinant human IgG antibodies (hIgGs) completely devoid of binding to Fcγ receptors
(FcγRs) and complement protein C1q, and thus with abolished immune effector functions …

We describe here the functional implications of an increase in IgG binding to the neonatal Fc
receptor. We have defined in a systematic fashion the relationship between enhanced FcRn …

Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the
potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte …

Cancer is the leading cause of death worldwide. Cancer immunotherapy involves
reinvigorating the patient's own immune system to fight against cancer. While novel …

The cell surface receptor for the vitamin folic acid (termed the folate receptor), is often
elevated in cancers of the ovary, kidney, lung, mammary gland, brain, endometrium, and …

With eleven therapeutic antibodies approved worldwide and many more in clinical trials,
research on antibody engineering has continued to escalate and expand. This review …

The invention relates to novel binding domain-immunoglo bulin fusion proteins that feature a
binding domain for a cognate structure Such as an antigen, a counterreceptor or the like, a …

Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin
effector function are provided, along with encoding nucleic acids, vectors and host cells as …